Privia Health Group, Inc. (PRVA) Stock Forecast
Data as of May 2, 2026Healthcare · Current price $24.76 (-0.36%)
Price Target Range
Consensus Price Target Over Time
Analyst Rating Distribution
Last 3 Months
6-Month Trend
Latest Analyst Forecasts
Price targets issued by Wall Street analysts. Upside calculated against today's price.
| Date | Analyst | Firm | Price Target | Upside |
|---|---|---|---|---|
| Feb 26, 2026 | Jack Slevin | Jefferies | $32.00 | +29.2% |
| Feb 26, 2026 | Jessica Tassan | Piper Sandler | $36.00 | +45.4% |
| Apr 15, 2025 | Michael Ha | Robert W. Baird | $26.00 | +5.0% |
| Jan 10, 2025 | Matthew Shea | Needham | $25.00 | +1.0% |
| Aug 26, 2024 | Michael Ha | Robert W. Baird | $24.00 | -3.1% |
| Aug 8, 2024 | Elizabeth Anderson | Evercore ISI | $22.00 | -11.1% |
| May 20, 2024 | Andrew Mok | Barclays | $19.00 | -23.3% |
| May 15, 2024 | Jailendra Singh | Truist Financial | $24.00 | -3.1% |
| Nov 17, 2022 | Canaccord Canaccord | Canaccord Genuity | $43.00 | +73.7% |
| Aug 12, 2022 | Sandy Draper | Guggenheim | $51.00 | +106.0% |
| Jul 25, 2022 | David MacDonald | Truist Financial | $40.00 | +61.6% |
Top Analysts Covering PRVA
PRVA vs Sector & Market
| Metric | PRVA | Healthcare Avg | Large Cap Avg |
|---|---|---|---|
| Analyst Rating | 2.17 | 2.24 | 2.41 |
| Analyst Count | 12 | 8 | 18 |
| Target Upside | +27.9% | +1150.2% | +14.9% |
| P/E Ratio | 141.97 | 6.74 | 31.19 |
Revenue Estimates
| Period | Low | Avg | High | # |
|---|---|---|---|---|
| 2026-12-31 | $2.37B | $2.39B | $2.40B | 12 |
| 2027-03-31 | $604M | $618M | $633M | 5 |
| 2027-06-30 | $633M | $648M | $663M | 5 |
| 2027-09-30 | $671M | $687M | $703M | 5 |
| 2027-12-31 | $655M | $671M | $686M | 5 |
| 2028-03-31 | $720M | $737M | $754M | 4 |
| 2028-06-30 | $731M | $749M | $767M | 4 |
| 2028-09-30 | $812M | $831M | $851M | 4 |
| 2028-12-31 | $779M | $798M | $817M | 4 |
| 2029-12-31 | $3.02B | $3.13B | $3.23B | 3 |
| 2030-12-31 | $3.33B | $3.45B | $3.56B | 6 |
EPS Estimates
| Period | Low | Avg | High | # |
|---|---|---|---|---|
| 2026-12-31 | $0.30 | $0.35 | $0.45 | 10 |
| 2027-03-31 | $0.09 | $0.10 | $0.10 | 3 |
| 2027-06-30 | $0.10 | $0.10 | $0.11 | 5 |
| 2027-09-30 | $0.14 | $0.14 | $0.14 | 3 |
| 2027-12-31 | $0.12 | $0.13 | $0.13 | 6 |
| 2028-03-31 | $0.13 | $0.14 | $0.14 | 4 |
| 2028-06-30 | $0.13 | $0.13 | $0.14 | 6 |
| 2028-09-30 | $0.18 | $0.19 | $0.19 | 4 |
| 2028-12-31 | $0.15 | $0.15 | $0.16 | 7 |
| 2029-12-31 | $0.76 | $0.79 | $0.82 | 1 |
| 2030-12-31 | $0.90 | $0.95 | $0.99 | 1 |
Frequently Asked Questions
What is the analyst consensus for PRVA?
The consensus among 12 analysts covering Privia Health Group, Inc. (PRVA) is Buy with an average price target of $31.00.
What is the highest price target for PRVA?
The highest price target for PRVA is $51.00, set by Sandy Draper at Guggenheim on 2022-08-12.
What is the lowest price target for PRVA?
The lowest price target for PRVA is $19.00, set by Andrew Mok at Barclays on 2024-05-20.
How many analysts cover PRVA?
12 analysts have issued ratings for Privia Health Group, Inc. in the past 12 months.
Is PRVA a buy or sell right now?
Based on 12 analyst ratings, PRVA has a consensus rating of Buy (2.17/5) with a +27.9% upside to the consensus target of $31.00.
What are the earnings estimates for PRVA?
Analysts estimate PRVA will report EPS of $0.35 for the period ending 2026-12-31, with revenue estimated at $2.39B.
Related Stock Forecasts
Data updated daily. Analyst price targets sourced from public filings and broker reports. Not investment advice.